Oral semaglutide pills: promising early data, real limitations

What did @therealdrleemd actually say?

The creator is calling orforglipron, Eli Lilly's experimental oral GLP-1 receptor agonist, a disappointment compared to injectable semaglutide (Ozempic/Wegovy). The core argument: Wegovy produces "14.9% weight loss" over 68 weeks, while orforglipron's available data shows only "7.9%" over 40 weeks. The conclusion is that the pill "kinda sucks" and patients shouldn't get their hopes up.

The framing is skeptical, which is refreshing compared to the relentless hype cycle around GLP-1s. But the comparison being made here has some real methodological problems that the creator glosses over pretty fast.

Does the science back this up?

Partially, but the head-to-head comparison is shakier than the creator implies. You simply cannot compare a 40-week readout to a 68-week endpoint and call it a fair fight.

The STEP 1 trial (Wilding et al., 2021, NEJM) established semaglutide 2.4 mg at 14.9% weight loss at 68 weeks. The orforglipron Phase 2 data (Wharton et al., 2023, NEJM) showed up to 9.4% weight loss at the highest dose tested (36 mg) at 36 weeks, not 7.9% as the creator states. The 7.9% figure appears to be from a lower dose arm or an earlier data cut. The Phase 2 trial was also not powered for a definitive weight loss endpoint the way STEP 1 was. Phase 3 results (the ATTAIN program) are still reading out, and those are the numbers that will actually matter for any real comparison.

What did they get wrong (or right)?

The creator got the general direction right: orforglipron is not going to match injectable semaglutide on current available data, and the hype has been excessive. Credit where it is due.

But a few things are worth flagging. First, the 7.9% figure is imprecise. The Wharton 2023 Phase 2 trial reported a dose-dependent range, with the highest dose group hitting 9.4% at 36 weeks. Using the lower number without context undersells where the drug might land with optimized dosing. Second, comparing a Phase 2 readout to a completed Phase 3 trial is not an apples-to-apples analysis. Phase 2 studies use smaller samples, shorter durations, and exploratory dosing. Third, the creator says "all the data's in" for the pill, which is flatly wrong. Eli Lilly's Phase 3 ATTAIN trials are ongoing, and the full efficacy picture does not exist yet.

What should you actually know?

Orforglipron is a non-peptide small molecule, which means it does not require refrigeration and can survive the digestive tract, unlike semaglutide oral (Rybelsus), which requires fasting and has poor bioavailability. That is a genuine engineering achievement with real access implications, particularly in lower-income countries and for patients with injection aversion.

The more honest framing here is that this pill, if Phase 3 delivers, might hit somewhere in the 10-15% weight loss range with optimized dosing. That is not nothing. It is also not Wegovy. Whether "good enough" is good enough depends entirely on the patient. A pill that produces 10% weight loss with no injection anxiety and no cold chain requirement may be the right tool for a large number of people. The creator's skepticism is healthy. The data cherrypicking is less so.